2C-C
2-(4-chloro-2,5-dimethoxyphenyl)ethanamine
Overview
2C-C belongs to Psychedelics / Phenethylamines / 2C series.
Effects
Subjective effects vary. What a substance feels like depends on dose, individual physiology,
mindset, and setting. The points below describe commonly reported effects, not guaranteed, uniform, or
desirable outcomes.
- Psychedelic sensory enhancement with altered visual patterning, more pronounced at higher doses
- Notably slow, gradual onset compared with 2C-B
- Comparatively less stimulating: often described as calm, sedating or relaxing
- Gentle, introspective character at common doses. Can become strongly visual toward the upper end of the range
Dosing & duration
Harm-reduction note: These are commonly cited reference ranges, not a recommendation or a
“safe” dose. Potency, purity, body chemistry, tolerance, and drug combinations vary widely. Start
low, go slow, wait for full effects before redosing, and never assume an unknown product matches these
figures. Missing data is not evidence of safety.
Oral
Dose ranges
Oral
20–40 mg
Duration
onset
Slow, roughly 1.5–2 h to full effects
total
4–8 h
Chemical & Physical Properties
| Formula | C10H14ClNO2 |
| Molar mass | 215.67 g/mol |
| State | Solid (usually the hydrochloride salt, white crystalline) |
| Melting point | 220–222 °C (hydrochloride salt) |
| Boiling point | Not reported |
| Density | Not reported |
| Vapor pressure | Not reported |
| pKa | Not reported |
| LogP | 2.1 (predicted, XLogP3) |
| Solubility | Not reported |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | Not reported |
| CAS (enantiomer) | |
| PubChem CID | 29979100 |
| InChIKey | CGKQFIWIPSIVAS-UHFFFAOYSA-N |
| InChI | InChI=1S/C10H14ClNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3 |
| SMILES | COC1=CC(=C(C=C1CCN)OC)Cl |
Synonyms
- 4-chloro-2,5-dimethoxyphenethylamine
- 2,5-dimethoxy-4-chlorophenethylamine
- 2C-C
Pharmacodynamics & Biochemistry
Serotonergic psychedelic phenethylamine with primary effects linked to agonist or partial-agonist activity at 5-HT2A receptors. Activity at other serotonin receptors such as 5-HT2C is also commonly discussed for the 2C-series phenethylamines. The overall profile is typically described as combining psychedelic sensory changes with a phenethylamine-like body component, and 2C-C is often characterised as one of the gentler, more introspective members of the 2C series.
Biological targets
- 5-HT2A
- 5-HT2C
Binding & functional measurements
| Target | Measurement | Species |
|---|---|---|
| 5-HT2A receptor | Ki 13 ± 5.0 nM | Human |
| 5-HT2C receptor | Ki 90 ± 26 nM | Human |
| 5-HT2B receptor | EC50 280 ± 110 nM Emax 81 ± 14% | Human |
| 5-HT1A receptor | Ki 190 ± 10 nM | Human |
| α2-adrenoceptor | Ki 530 ± 60 nM | Human |
| D2 receptor | Ki 2,100 ± 400 nM | Human |
| 5-HT2A receptor | EC50 19 nM Emax 91.2% | Human |
| 5-HT2C receptor | EC50 78 ± 5.5 nM Emax 29% | Human |
| TAAR1 | Ki 110 ± 20 nM | Rat |
| TAAR1 | EC50 340 ± 150 nM Emax 51 ± 14% | Rat |
| TAAR1 | Ki 4,100 ± 300 nM | Mouse |
| TAAR1 | EC50 2,300 ± 1,500 nM Emax 57 ± 23% | Mouse |
Pharmacokinetics
| Bioavailability | Not reported |
| Tmax | Not reported |
| Half-life | Moderate |
| Vd | Not reported |
| Protein binding | Not reported |
| Metabolism | Hepatic |
| Excretion | Not reported |
Toxicology & Safety
Harm-reduction note: Toxicity and risk depend on dose, route, purity, combinations, setting, and individual
health factors. Missing harms should never be interpreted as evidence of safety.
Not reported
As a serotonergic 2C psychedelic, 2C-C can acutely cause anxiety, panic, confusion, nausea and perceptual overwhelm, alongside sympathomimetic effects such as tachycardia, hypertension, mydriasis and vasoconstriction. Risk rises with higher doses, hot or crowded settings, adulteration, and combination with stimulants or other serotonergic drugs. Formal human toxicity data are very limited. Rodent studies report abuse-potential-like behaviour and neurotoxicity, which should not be extrapolated directly to humans but underline that safety is not established. Limited literature must never be read as evidence of safety.[4][5][6][7][8][2][3]
Legal Status
Legal note: Legal status can change over time and may vary by country, region, formulation, analogue status,
prescription context, and enforcement practice. Always confirm with current official sources before relying on this section.
US: Schedule I. UK: Class A. DE: BtMG Anlage I
Interactions & Contraindications
Drug interactions
SSRIs, SNRIs, Lithium, Tramadol, Other serotonergic drugs Can add to serotonergic load and, in principle, raise the risk of serotonin toxicity.
MAOIs May intensify and prolong effects unpredictably, warranting particular caution.
Stimulants (amphetamines, cocaine) Compound cardiovascular strain, anxiety, vasoconstriction and overheating risk.
Contraindications
Personal or family history of psychosis, schizophrenia or bipolar disorder
Cardiovascular disease, hypertension or arrhythmia significant or uncontrolled disease or hypertension.
Concurrent MAOI, SSRI/SNRI or other serotonergic medication concurrent MAO inhibitors.
Hot, dehydrating environments (overheating risk) or heavy stimulant co-use.
No interactions or contraindications listed.
Usage & Context
- Research.
Sources & Evidence
- Shulgin A, Shulgin A (1991). PiHKAL: A Chemical Love Story — entry #22 (2C-C)
- Kim YJ, Ma SX, Hur KH, et al. (2021). New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents. Arch Toxicol 95:1413-1429.
PMID 33515270 · doi:10.1007/s00204-021-02980-x
- Gil-Martins E, Barbosa DJ, Borges F, et al. (2025). Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?. Toxicol Rep 14:101890.
PMID 39867514 · doi:10.1016/j.toxrep.2025.101890
- Rickli A, Luethi D, Reinisch J, et al. (2015). Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546-53.
PMID 26318099 · doi:10.1016/j.neuropharm.2015.08.034
- Eshleman AJ, Forster MJ, Wolfrum KM, et al. (2014). Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology (Berl) 231:875-88.
PMID 24142203 · doi:10.1007/s00213-013-3303-6
- Elmore JS, Decker AM, de la Fuente Revenga M, et al. (2018). Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:54-65.
PMID 29501528 · doi:10.1016/j.neuropharm.2018.02.033
- Simmler LD, Buchy D, Chaboz S, et al. (2016). In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1. J Pharmacol Exp Ther 357:134-44.
PMID 26791601 · doi:10.1124/jpet.115.229765
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-7.
PMID 17223101 · doi:10.1016/j.ejphar.2006.11.075
- Pottie E, Cannaert A, Stove CP (2020). In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor. Arch Toxicol 94:3449-3460.
PMID 32627074 · doi:10.1007/s00204-020-02836-w